John Vann
Advanced Heart Failure and Transplant Cardiology · Tulsa, OKNPI 1326415050
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $7,489 of the $9,025 with a category attached, or 83.0%. 33 manufacturers reported payments, led by Abbott at 49.0% of the total. 2025 is the largest year on record at $2,956, 4.6 times the $636 reported in 2019.
Across 264 payments — averaging $34.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$4K
- Novartis$793
- Abiomed$679
- Amgen$328
- Boston Scientific$299
- AstraZeneca$278
- plus $2K from 27 others
What the payments were for
- Travel & lodging$1,33715%
- Food & beverage$7,48983%
- Education$1992%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 68 | $4,424 |
| Novartis | 50 | $793 |
| Abiomed | 11 | $679 |
| Amgen | 19 | $328 |
| Boston Scientific | 6 | $299 |
| AstraZeneca | 15 | $278 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 9 | $210 |
| E.r. Squibb & Sons, L.L.C. | 12 | $196 |
| Penumbra, Inc. | 1 | $165 |
| Actelion Pharmaceuticals US, Inc. | 4 | $155 |
| Merck | 10 | $155 |
| Pfizer | 9 | $147 |
| Inari Medical, Inc. | 2 | $107 |
| Medtronic(2 entities) | 2 | $106 |
| Astellas Pharma US Inc | 1 | $100 |
| Boehringer Ingelheim | 6 | $92 |
| Edwards Lifesciences | 1 | $92 |
| Philips North America LLC | 5 | $91 |
| Esperion Therapeutics, Inc. | 4 | $76 |
| Alnylam Pharmaceuticals Inc. | 3 | $75 |
| Johnson & Johnson | 4 | $73 |
| Lexicon Pharmaceuticals, Inc. | 4 | $68 |
| Cvrx, Inc. | 3 | $53 |
| Novo Nordisk | 3 | $49 |
| Angiodynamics, Inc. | 2 | $39 |
| Bayer | 2 | $35 |
| Chiesi USA, Inc. | 2 | $30 |
| Impulse Dynamics (USA) Inc. | 1 | $21 |
| Baxter Healthcare | 1 | $20 |
| Cardiac Dimensions, Inc. | 1 | $19 |
| Silk Road Medical, Inc. | 1 | $19 |
| Bridgebio Pharma, Inc. | 1 | $16 |
| Lilly USA, LLC | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
Too few advanced heart failure and transplant cardiology providers in Oklahomato place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 359 | $327,227 |
| EntrestoSacubitril/Valsartan | 89 | $121,177 |
| JardianceEmpagliflozin | 88 | $93,493 |
| XareltoRivaroxaban | 121 | $89,648 |
| FarxigaDapagliflozin Propanediol | 34 | $34,501 |
| BrilintaTicagrelor | 29 | $13,139 |
| Atorvastatin Calcium | 211 | $4,184 |
| Metoprolol Succinate | 196 | $3,793 |
| Rosuvastatin Calcium | 118 | $2,772 |
| Ezetimibe | 69 | $2,671 |
| ClopidogrelClopidogrel Bisulfate | 147 | $2,641 |
| Amlodipine Besylate | 232 | $2,246 |
| Amiodarone Hcl | 101 | $1,965 |
| Carvedilol | 152 | $1,559 |
| Losartan Potassium | 132 | $1,394 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $147 | $327,227359 claims |
| NovartisEntresto | $793 | $121,17789 claims |
| Boehringer IngelheimJardiance | $92 | $93,49388 claims |
| Johnson & JohnsonXarelto | $73 | $89,648121 claims |
| AstraZenecaFarxiga, Brilinta | $278 | $47,64063 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few advanced heart failure and transplant cardiology providers in Oklahomaon file to place this against a meaningful peer group, so we don't.
Other advanced heart failure and transplant cardiology in Tulsa
- Steven StroudTulsa$39K
- Luis Meggo QuirozTulsa$19K
- Ralph EnsleyTulsa$11K
- Nina WilliamsTulsa$5K
- Luke CunninghamOklahoma City$70K
- Tarun DasariOklahoma City$2K
- Carol KepfordOklahoma City$716
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.